Analyst Ratings For Bristol-Myers Squibb Co (NYSE:BMY)
Today, BMO Capital Markets reiterated its Buy rating on Bristol-Myers Squibb Co (NYSE:BMY) with a price target of $59.00.
There are 12 Hold Ratings, 7 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Bristol-Myers Squibb Co (NYSE:BMY) is Hold with a consensus target price of $59.4953 per share, a potential 15.14% upside.
Some recent analyst ratings include
- 2/19/2019-Bristol-Myers Squibb Co (NYSE:BMY) had its Buy rating reiterated by BMO Capital Markets with a $59.00 price target
- 2/15/2019-Bristol-Myers Squibb Co (NYSE:BMY) had its Hold rating reiterated by Credit Suisse Group with a $59.00 price target
- 1/15/2019-Bristol-Myers Squibb Co (NYSE:BMY) gets upgraded to Buy by Societe Generale
- 1/4/2019-Bristol-Myers Squibb Co (NYSE:BMY) gets downgraded to Hold by Edward Jones
- 11/27/2018-Bristol-Myers Squibb Co (NYSE:BMY) had its Outperform rating reiterated by William Blair
- On 4/30/2018 Dinesh C Paliwal, Director, bought 4,770 with an average share price of $52.40 per share and the total transaction amounting to $249,948.00.
- On 12/15/2017 Theodore R Samuels II, Director, bought 4,000 with an average share price of $62.30 per share and the total transaction amounting to $249,200.00.
- On 12/12/2017 Thomas J Jr. Lynch, EVP, sold 5,300 with an average share price of $63.24 per share and the total transaction amounting to $335,172.00.
- On 12/4/2017 Sandra Leung, EVP, sold 156,582 with an average share price of $63.37 per share and the total transaction amounting to $9,922,601.34.
- On 9/6/2017 Joseph C Caldarella, SVP, sold 9,340 with an average share price of $60.00 per share and the total transaction amounting to $560,400.00.
- On 8/2/2017 Theodore R Samuels II, Director, bought 6,000 with an average share price of $55.94 per share and the total transaction amounting to $335,640.00.
- On 4/7/2017 Lamberto Andreotti, Director, sold 34,000 with an average share price of $53.26 per share and the total transaction amounting to $1,810,840.00.
About Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; Mirati Therapeutics, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Recent Trading Activity for Bristol-Myers Squibb Co (NYSE:BMY)
Shares of Bristol-Myers Squibb Co closed the previous trading session at 51,67 +0,84 1,65 % with 50.92 shares trading hands.